A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
about
Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsSynthesis and biochemical characterization of EGF receptor in a water-soluble membrane model systemCombination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinomaPhase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer.A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells.Array CGH analysis of the rare laryngeal basaloid squamous cell carcinoma: a case report.HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neckA possible strategy against head and neck cancer: in silico investigation of three-in-one inhibitors.Stability-Diversity Tradeoffs Impose Fundamental Constraints on Selection of Synthetic Human VH/VL Single-Domain Antibodies from In Vitro Display Libraries.Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients.Efficacy of radiotherapy on intermediate and advanced lung cancer and its effect on dynamic changes of serum vascular endothelial growth factor and matrix metalloproteinase-9.
P2860
Q28086768-281E6611-809C-499F-A5CA-EB253EA43230Q33769117-0CC32ECD-03CA-41A5-AE53-E43635550E8CQ33875560-C695CFC2-98CF-4B4B-9350-92331AEDDFF8Q34754728-EE7EFD2F-1694-4E12-9B3D-5BA7BAE05D80Q36213205-8D521F2F-6971-46FA-8BD0-7CDE3BAD1182Q36305380-4822C73A-31E1-4807-8449-77A40E3B036EQ38760738-1B0A4D24-C1BA-4C1D-B640-CD37BA33C177Q41513098-5E84CEC7-9DB2-44A2-904A-B54154E42E19Q44999449-BDD0FC35-2647-4889-8571-EA9DFE9EC6FCQ49358130-12C73BC7-6616-497A-BE2F-FCD316C4BA16Q50323216-4116C6E5-B1F9-4168-94D2-7993FBF4DAC7Q55342307-D270C59D-1F45-4F98-A400-CCEEF133A6F9
P2860
A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
@en
A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
@nl
type
label
A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
@en
A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
@nl
prefLabel
A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
@en
A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
@nl
P2093
P2860
P356
P1476
A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment
@en
P2093
Daniel Rycroft
Dong M Shin
Hongzheng Zhang
Hyung Ju C Shin
Lydia Koenig
Michael Steward
Mourad Tighiouart
Sreenivas Nannapaneni
Steve D Holmes
P2860
P304
P356
10.1002/IJC.26427
P50
P577
2011-11-19T00:00:00Z